FAST Enough for Intracerebral Hemorrhage?

By J. Claude Hemphill III, MD, MAS - The results of the FAST (Factor Seven for Acute Hemorrhagic Stroke) trial, published in the May 15, 2008, issue of The New England Journal of Medicine (NEJM), reaffirmed previous studies’ findings that rFVIIa decreases hematoma expansion, but in this phase III study there was no effect on mortality or functional outcome. rFVIIa treatment was associated with an increase in thromboembolic events, principally subendocardial myocardial infarctions. FAST raises several important issues for future clinical trials for this devastating condition.
Read More

07-04-2008